RCS - Faron Pharma. Oy - Poster Presentations at AACR 2023

Faron Pharmaceuticals OyAnnouncement

18/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230418:nRSR4964Wa&default-theme=true

RNS Number : 4964W  Faron Pharmaceuticals Oy  18 April 2023

Faron Pharmaceuticals Oy

 

("Faron" or the "Company")

 

Faron Pharmaceuticals Announces Poster Presentations on Bexmarilimab at the
American Association for Cancer Research Annual Meeting 2023

 

Press Release, April 18, 2023

 

TURKU, FINLAND / BOSTON, MA: Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), a clinical-stage biopharmaceutical company focused on tackling
cancers via novel immunotherapies, announces the presentation of two posters
at the American Association for Cancer Research Annual Meeting 2023 in
Orlando, Florida.

 

Details of the poster presentations are as follows:

 

 Title:        CLEVER-1/PD-L1 ratio predicts response to bexmarilimab, a novel
               macrophage-guided immunotherapy, in immune-deprived cancers
 Abstract ID:  Section 37, Board 9
 Date/Time:    Tuesday, April 18, 9:00 a.m. EST

 

 Title:        Bexmarilimab induces B-cell activation and autoantibody production
 Abstract ID:  Section 43, Board 16
 Date/Time:    Monday, April 17, 9:00 a.m. EST

 

The first poster indicates a PD-L1/CLEVER-1 IHC staining ratio may be used to
predict bexmarilimab response, as responding patients have a low PD-L1 and
high CLEVER-1 staining, as well as low inflammatory cytokine (IFNγ, TNFα,
IL-6) levels as reported previously. This finding means they are often
refractory to checkpoint inhibitors and other T cell activating agents.

 

"The finding supports patient selection for planned combination studies with
PD-1 blockade refractory patients," said CEO Dr. Markku Jalkanen. Indications
in the upcoming BEXCOMBO study include metastatic head and neck squamous cell
carcinoma, urothelial carcinoma and non-small cell lung cancer where
first-line PD-1 blockade is the approved standard of care.

 

The second poster indicates that bexmarilimab can induce activation and
secondary Ig rearrangements in mature B-cells. B-cell diversity and activation
is considered important for cancer immune recognition.

 

The abstracts will be available in the AACR journal Cancer Research.

 

For more information please contact:

 

Media Contact

Faron Pharmaceuticals

Jennifer C. Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com (mailto:Jennifer.Smith-Parker@faron.com)

 

Investor Contact

Faron Pharmaceuticals

Julia Balanova

VP, Investor Relations

julia.balanova@faron.com (mailto:julia.balanova@faron.com)

investor.relations@faron.com (mailto:investor.relations@faron.com)

Phone: +1 (917) 306-6096

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

David Daley, Lindsey Neville, Namrata Taak

faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

 

About Bexmarilimab

Bexmarilimab is Faron's wholly owned, investigational immunotherapy with the
potential to provide immune stimulation for treatment-resistant cancers
through targeting myeloid cell function. A novel anti-CLEVER-1 humanized
antibody, bexmarilimab targets CLEVER-1 positive (Common Lymphatic Endothelial
and Vascular Endothelial Receptor 1) tumor-associated macrophages (TAMs) in
the tumor microenvironment, converting highly immunosuppressive M2 macrophages
to immune-stimulating M1 macrophages. As an immuno-oncology therapy,
bexmarilimab has therapeutic potential in combination with other standard
treatments including immune checkpoint molecules in both solid tumors and
hematologic malignancies.

 

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), together with its
subsidiaries, is a clinical stage biopharmaceutical group focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer. Bexmarilimab, a novel anti-CLEVER-1 humanized antibody, is its
investigational immunotherapy with the potential to remove immunosuppression
of cancers through targeting myeloid cell function. Bexmarilimab is being
investigated in Phase I/II clinical trials as a potential therapy for patients
with hematological and solid cancers in combination with other standard
treatments including immune checkpoint molecules. Faron is headquartered in
Turku, Finland. Further information is available at www.faron.com.

 

 

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be,
forward-looking statements. Forward looking statements are identified by their
use of terms and phrases such as ''believe'', ''could'', "should", "expect",
"hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'',
''potentially'', ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions. These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the
results and expectations discussed in the forward-looking statements, many of
which are beyond the control of the Company. In addition,  other factors
which could cause actual results to differ materially include the ability of
the Company to successfully license its programs within the anticipated
timeframe or at all, risks associated with vulnerability to general economic
and business conditions, competition, environmental and other regulatory
changes, actions by governmental authorities, the availability of capital
markets or other sources of funding, reliance on key personnel, uninsured and
underinsured losses and other factors.  Although any forward-looking
statements contained in this announcement are based upon what the Directors
believe to be reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward-looking statements.
Accordingly, readers are cautioned not to place undue reliance on
forward-looking statements. Subject to any continuing obligations under
applicable law or any relevant AIM Rule requirements, in providing this
information the Company does not undertake any obligation to publicly update
or revise any of the forward-looking statements or to advise of any change in
events, conditions or circumstances on which any such statement is based.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKLXFSKDEFA